Concord Healthcare Group Co. Ltd. (China)

The Company was incorporated in the People's Republic of China (the “PRC”) on July 23, 2008 with limited liability under the Companies laws of the PRC. The Company share were listed on the Main Board of the Stock Exchange of Hong Kong Limited on Tuesday, January 9,2024. The Company's principal place of business is located in the PRC. The Company and its subsidiaries (the “Group”) are principally engaged in leasing of radiotherapy and diagnostic imaging equipment, trading of radiotherapy and diagnostic imaging equipment, provision of management and technical services to hospitals, sales and installing of medical equipment and software, and provision of premium cancer treatment services.
HISTORY
The following table sets forth major events and milestones in the development of business:
2008 The Company was established under the laws of the PRC and commenced operation of medical equipment, software and related services.
2011 The medical equipment, software and related services accumulated nine customers covering seven provinces in China as of December 31, 2011.
2014 Datong Hospital was established by the Group.
Datong Hospital, the first independent Class II cancer specialty hospital under control, received the Medical Institution Practicing License.
2016 The Company was became listed on the NEEQ.
2017 Datong Hospital commenced operation.
The Company was commenced the construction of Shanghai Hospital, which was expected to commence operation in January 2026.
2018 The Company was acquired Guangzhou Hospital and Shanghai Outpatient Center.
Shanghai Imaging Center was established by the Group together with other promoters.
2020 Shanghai Imaging Center, an independent imaging diagnostic center, commenced full operation.
The Company was acquired Guangzhou Outpatient Center.
The internally-formulated Practice Guideline for Total Body Irradiation Technology was approved by the National Cancer Center of China as the 2019
Radiation Therapy Quality Control Guidelines (2019 ), which was the first approved project hosted by a private medical institution in China.
The Company was launched Jiahe Yunying Remote Imaging Information Diagnosis Platform for medical equipment, software and related services.
2021 The Company was launched Jiahe Cloud Asset Management Platform for medical equipment, software and related services.
The Company was launched Jiahe Feiyun Intelligent Radiation Therapy Cloud Service Platform for medical equipment, software and related services.
The Company was launched Internet Hospital as a one-stop portal to connect cancer patients with comprehensive oncology healthcare resources.
Guangzhou Hospital, a comprehensive cancer hospital commenced operation.
The Company was acquired Beijing Healthingkon, an AI-orientated company which was certified by China Academy of China Medical Sciences for its top
notch AI-driven Traditional Chinese Medicine Tongue Diagnosis technology ensuing the application of AI engine.
2022 The Company was chosen by the National Cancer Center of China to be an editor for the formulation of the 2021 version of the National Standard of
Radiation Therapy Quality Control Guidelines, and have initiated two national standard formulation projects to develop Radiation Therapy Data Validation
Quality Control Practice Guidelines and Development Guidelines for the 5G-based Remote Radiation Therapy Plan Design, Implementation and Quality
Control Platform.
2023 The Company was chosen by the National Cancer Center of China to be an editor for the formulation of the 2023 version of the National Standard of
Radiation Therapy Quality Control Guidelines, and initiated a national standard formulation projects to develop Practice Guideline for Total Skin (E-beam)
Irradiation Technology.